StoxGland Pharma vs Anthem Biosciences: share price & financials comparison
NSE: GLAND vs ANTHEM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Gland Pharma vs Anthem Biosciences at a glance
Gland Pharma (GLAND) has a market capitalisation of ₹52,281 Cr, against ₹51,594 Cr for Anthem Biosciences (ANTHEM). Over the past year Gland Pharma has returned +66.4%, compared with +26.0% for Anthem Biosciences. On valuation, Gland Pharma trades at a lower P/E of 46.3 versus 271.9. Gland Pharma earns a higher return on equity (10.9% vs 5.8%). Gland Pharma comes out ahead on size, valuation, profitability, growth, momentum and technicals. Anthem Biosciences comes out ahead on financial health. Across the scored metrics below, Gland Pharma leads on 9 and Anthem Biosciences on 3. On StoxGud's 10-point checklist, Gland Pharma scores 9/10 and Anthem Biosciences scores 6/10.
| Metric | Gland Pharma | Anthem Biosciences |
|---|---|---|
| Size | ||
| Market cap | ₹52,281 Cr | ₹51,594 Cr |
| Revenue (latest FY) | ₹6,431 Cr | ₹2,124 Cr |
| Net profit (latest FY) | ₹1,027 Cr | ₹592 Cr |
| Valuation | ||
| P/E | 46.3 | 271.9 |
| P/B | 5.05 | 15.73 |
| Dividend yield | 0.57% | — |
| Profitability | ||
| Return on equity | 10.9% | 5.8% |
| Net profit margin | 16.8% | 9.3% |
| Operating margin | 26.0% | 41.4% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | +8.0% |
| Net profit growth (YoY) | +47.1% | — |
| Revenue CAGR (multi-year) | +13.2% | — |
| Financial health | ||
| Debt to equity | 0.02 | 0.01 |
| Momentum | ||
| 1-month return | +0.6% | +3.2% |
| 1-year return | +66.4% | +26.0% |
| 3-year CAGR | +26.2% | — |
| 5-year CAGR | -2.8% | — |
| Distance from 52W high | +0.0% | -4.4% |
| Technicals | ||
| RSI (14) | 60 | 81 |
| Price vs 200-day avg | +37.2% | +18.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Gland Pharma | Anthem Biosciences |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Gland Pharma or Anthem Biosciences?
Gland Pharma has a market cap of ₹52,281 Cr and Anthem Biosciences has a market cap of ₹51,594 Cr as of 06 Nov 2026.
Which has a lower P/E, Gland Pharma or Anthem Biosciences?
Gland Pharma has the lower P/E: Gland Pharma trades at 46.3 and Anthem Biosciences at 271.9.
Which gave better returns in the last year, Gland Pharma or Anthem Biosciences?
Gland Pharma did better: Gland Pharma returned +66.4% and Anthem Biosciences returned +26.0% over one year.
Is Gland Pharma or Anthem Biosciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Gland Pharma scores 9/10 and Anthem Biosciences scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.